„Johnson & Johnson“ akcijos pakilo pasibaigus kūdikių miltelių pardavimui

Atnaujinta 5:35 EST

Johnsonas ir Johnsonas (JNJ) shares edged higher Friday after the consumer healthcare group said it would completely halt the sale of its iconic talc-based baby powder products next year.

Johnson & Johnson, which faces around 38,000 lawsuits centered around links to cancer-causing asbestos found in the talc-based product , stopped selling Baby Powder in the U.S. and Canada in 2020. The group, which began selling talc-based Baby Powder in 1894, said late Thursday that it will transition to “an all cornstarch-based baby powder portfolio” starting in 2023.

Late last year, Johnson & Johnson noted that costs linked to defending cases linked to allegations that its Baby Powder, and other talc-based products, contained cancer-causing asbestos are close to $1 billion. Another $3.5 billion has been tied to previous verdicts and settlements.

Slinkite iki Tęsti

The group then spun-off a specially-created subsidiary, LTL Management LLC, to house all of its talc-related litigation liabilities that immediately filed for bankruptcy protection in North Carolina, with the case ultimately transferred to a court in New Jersey.

Johnson & Johnson shares were marked 0.4% higher in pre-market trading to indicate an opening bell price of $167.79 each.

Source: https://www.thestreet.com/markets/johnson-johnson-stock-higher-after-ending-baby-powder-sales?puc=yahoo&cm_ven=YAHOO&yptr=yahoo